226 related articles for article (PubMed ID: 29993147)
21. Yttrium 90 ibritumomab tiuxetan in lymphoma.
Cheung MC; Haynes AE; Stevens A; Meyer RM; Imrie K;
Leuk Lymphoma; 2006 Jun; 47(6):967-77. PubMed ID: 16840185
[TBL] [Abstract][Full Text] [Related]
22. 90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.
Blum KA; Bartlett NL
Expert Opin Biol Ther; 2004 Aug; 4(8):1323-31. PubMed ID: 15268665
[TBL] [Abstract][Full Text] [Related]
23. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
Jacene HA; Filice R; Kasecamp W; Wahl RL
J Nucl Med; 2007 Nov; 48(11):1767-76. PubMed ID: 17942813
[TBL] [Abstract][Full Text] [Related]
24. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
Esmaeli B; McLaughlin P; Pro B; Samaniego F; Gayed I; Hagemeister F; Romaguera J; Cabanillas F; Neelapu SS; Banay R; Fayad L; Wayne Saville M; Kwak LW
Ann Oncol; 2009 Apr; 20(4):709-14. PubMed ID: 19150940
[TBL] [Abstract][Full Text] [Related]
25. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma.
Tobinai K; Watanabe T; Ogura M; Morishima Y; Hotta T; Ishizawa K; Itoh K; Okamoto S; Taniwaki M; Tsukamoto N; Okumura H; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Hayashi M; Endo K
Cancer Sci; 2009 Jan; 100(1):158-64. PubMed ID: 19018755
[TBL] [Abstract][Full Text] [Related]
26. [90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab].
Aurer I; Huić D; Zuvić M; Sever-Prebilić M; Ajduković R; Radman I; Skare-Librenjak L; Ostojić-Kolonić S; Labar B
Lijec Vjesn; 2006; 128(7-8):224-7. PubMed ID: 17087138
[TBL] [Abstract][Full Text] [Related]
27. 90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma.
Hoffmann M; Troch M; Eidherr H; Traub-Weidinger T; Jonak C; Muellauer L; Raderer M
Leuk Lymphoma; 2011 Jan; 52(1):42-5. PubMed ID: 21133720
[TBL] [Abstract][Full Text] [Related]
28. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
Witzig TE; Molina A; Gordon LI; Emmanouilides C; Schilder RJ; Flinn IW; Darif M; Macklis R; Vo K; Wiseman GA
Cancer; 2007 May; 109(9):1804-10. PubMed ID: 17380530
[TBL] [Abstract][Full Text] [Related]
29. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
[TBL] [Abstract][Full Text] [Related]
30. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma.
Samaniego F; McLaughlin P; Neelapu SS; Feng L; Fanale M; Nastoupil L; Rodriguez MA; Pro B; Taylor E; Hagemeister FB; Fowler N
Leuk Lymphoma; 2021 Jan; 62(1):58-67. PubMed ID: 32924687
[TBL] [Abstract][Full Text] [Related]
31. Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan.
Cicone F; Russo E; Carpaneto A; Prior JO; Delaloye AB; Scopinaro F; Ketterer N
Hematol Oncol; 2011 Sep; 29(3):131-8. PubMed ID: 20862654
[TBL] [Abstract][Full Text] [Related]
32. Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.
Provencio M; Cruz Mora MÁ; Gómez-Codina J; Quero Blanco C; Llanos M; García-Arroyo FR; de la Cruz L; Gumá Padró J; Delgado Pérez JR; Sánchez A; Alvarez Cabellos R; Rueda A;
Leuk Lymphoma; 2014 Jan; 55(1):51-5. PubMed ID: 23573825
[TBL] [Abstract][Full Text] [Related]
33. Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life.
Andrade-Campos MM; Montes-Limón AE; Soro-Alcubierre G; Grasa JM; Lopez-Gómez L; Baringo T; Giraldo P
Ann Hematol; 2014 Dec; 93(12):1985-92. PubMed ID: 24985089
[TBL] [Abstract][Full Text] [Related]
34. Consolidation with
Miura K; Tsujimura H; Masaki Y; Iino M; Takizawa J; Maeda Y; Yamamoto K; Tamura S; Yoshida A; Yagi H; Yoshida I; Kitazume K; Masunari T; Choi I; Kakinoki Y; Suzuki R; Yoshino T; Nakamura S; Hatta Y; Yoshida T; Kanno M
Hematol Oncol; 2021 Feb; 39(1):51-59. PubMed ID: 32978820
[TBL] [Abstract][Full Text] [Related]
35. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
Weigert O; Illidge T; Hiddemann W; Dreyling M
Cancer; 2006 Aug; 107(4):686-95. PubMed ID: 16826593
[TBL] [Abstract][Full Text] [Related]
36. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome.
Tsimberidou AM; Murray JL; O'Brien S; Wierda WG; Keating MJ
Cancer; 2004 May; 100(10):2195-200. PubMed ID: 15139064
[TBL] [Abstract][Full Text] [Related]
37. A randomized phase II study comparing consolidation with a single dose of
López-Guillermo A; Canales MÁ; Dlouhy I; Mercadal S; Briones J; Martín García-Sancho A; Sancho JM; Moraleda JM; Terol MJ; Salar A; Palomera L; Gardella S; Jarque I; Ferrer S; Bargay J; López A; Panizo C; Muntañola A; Montalbán C; Conde E; Hernández MT; Soler A; García Marco JA; Deben G; Marín J; Tomás JF;
Leuk Lymphoma; 2022 Jan; 63(1):93-100. PubMed ID: 34459702
[TBL] [Abstract][Full Text] [Related]
38. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.
Morschhauser F; Dreyling M; Rohatiner A; Hagemeister F; Bischof Delaloye A
Oncologist; 2009; 14 Suppl 2():17-29. PubMed ID: 19819921
[TBL] [Abstract][Full Text] [Related]
39. FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.
Pisani F; Maini CL; Sciuto R; Dessanti L; D'Andrea M; Assisi D; Petti MC
J Exp Clin Cancer Res; 2011 Feb; 30(1):16. PubMed ID: 21303501
[TBL] [Abstract][Full Text] [Related]
40. [Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas].
Setoain X; López-Guillermo A; Ruiz A; Pons F
Rev Esp Med Nucl; 2006; 25(1):55-68; quiz 69-70.. PubMed ID: 16540015
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
